We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01111981
Recruitment Status : Unknown
Verified April 2010 by Callender Center for Clinical Research.
Recruitment status was:  Recruiting
First Posted : April 28, 2010
Last Update Posted : April 28, 2010
Sponsor:
Information provided by:
Callender Center for Clinical Research

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The purpose of this study is to ascertain the safety and efficacy of

Clobetasol Propionate 0.05% E Foam in the treatment of Central Centrifugal

Cicatricial Alopecia.


Condition or disease Intervention/treatment Phase
Alopecia Drug: Clobetasol Propionate 0.05% Emollient Foam Phase 4

Detailed Description:

Central Centrifugal Cicatricial Alopecia (CCCA) is an inflammation-induced

hair loss starting in the central scalp and progressing centrifugally. The

cause of CCCA is unknown. Early diagnosis and treatment is essential to stop

or slow the progression of scarring and permanent hair loss. Once scarring

occurs, the hair follicles are obliterated and the hair cannot regrow. Thus,

anti-inflammatory medications are used to decrease inflammation. Current

treatment includes topical and intralesional corticosteroids, oral

antibiotics, and hair transplantation, all which may take months to years to

show improvement. There is no evidence-based medicine on how to treat

primary cicatricial alopecias. Clobestasol Propionate 0.05% Emollient Foam is

an FDA-approved and marketed topical corticosteroid for the treatment of the

inflammatory and pruritic manifestations of moderate to severe corticosteroid-

responsive dermatoses of the scalp. Many studies found the foam to be less

irritating than the original formulation.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in the Treatment of Central Centrifugal Cicatricial Alopecia
Study Start Date : October 2009
Estimated Primary Completion Date : February 2010
Estimated Study Completion Date : October 2010

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Intervention Details:
  • Drug: Clobetasol Propionate 0.05% Emollient Foam
    Clobetasol Propionate 0.05% E Foam to be applied to affected area once a day for 16 weeks
    Other Name: Olux-E

Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Improvement of pruritis, tenderness, and pain [ Time Frame: 4 months ]

Secondary Outcome Measures :
  1. Absence of inflammation on biopsy [ Time Frame: 4 months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with CCCA, treated or untreated
  • Score 0 - 1 on Scale/Questionnaire
  • 18 years of age or older
  • Women of African descent

Exclusion Criteria:

  • Score > 1 on Scale/Questionnaire
  • Alopecias other than CCCA, including alopecia arreata, lichen planopilaris, trichotillomania, and traction alopecia
  • History of hair transplantation
  • Children less than 18 years of age
  • Males
  • Women of non-African descent
  • Pregnancy or breastfeeding. Women of childbearing age must use reliable forms of contraception (e.g., abstinence, oral contraceptives, or spermicide and condoms)
  • Anti-dandruff shampoo within 30 days
  • Anti-inflammatory medications such as antibiotics (doxycycline, minocycline, rifampin, etc.), steroids (oral prednisone, topical corticosteroids,etc.), NSAIDs (ibuprofen, aspirin, etc.)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01111981


Contacts
Layout table for location contacts
Contact: Lynn Carter, BA 301-249-0970 clinresearch@callenderskin.com
Contact: Cherie Young, M.D. 301-249-0970 clinresearch@callenderskin.com

Locations
Layout table for location information
United States, Maryland
Callender Center for Clinical Research Recruiting
Mitchellville, Maryland, United States, 20721
Contact: Lynn Carter, BA    301-249-0970    clinresearch@callenderskin.com   
Contact: Niccole Mathews    301-249-0970    clinresearch@callenderskin.com   
Sponsors and Collaborators
Callender Center for Clinical Research
Investigators
Layout table for investigator information
Principal Investigator: Valerie Callender, M.D. Callender Skin for Clinical Research
Study Director: Cherie Young, M.D. Callender Center for Clinical Research
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Valerie Callender, M.D., Callender Center for Clinical Research
ClinicalTrials.gov Identifier: NCT01111981    
Other Study ID Numbers: VDC2009O
First Posted: April 28, 2010    Key Record Dates
Last Update Posted: April 28, 2010
Last Verified: April 2010
Keywords provided by Callender Center for Clinical Research:
alopecia
CCCA - Central Centrifugal Cicatricial Alopecia
Additional relevant MeSH terms:
Layout table for MeSH terms
Alopecia
Alopecia Areata
Hypotrichosis
Hair Diseases
Skin Diseases
Pathological Conditions, Anatomical
Clobetasol
 Emollients
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Dermatologic Agents